2. Search Result
Search Result
Results for "

Werner

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148699
    HRO761
    3 Publications Verification

    Werner syndrome RecQ helicase-IN-1

    		 DNA/RNA Synthesis Cancer
    HRO761 (Werner syndrome RecQ helicase-IN-1) (example 42) is a potent Werner syndrome RecQ DNA helicase enzyme (WRN) inhibitor and can be used in cancer research .
    HRO761
  • HY-110185
    NSC 617145
    3 Publications Verification

    		 DNA/RNA Synthesis Cancer
    NSC 617145 is a selective werner syndrome helicase (WRN) helicase inhibitor with an IC50 value of 230 nM. NSC 617145 inhibits WRN ATPase, and induces double-strand breaks (DSB) and chromosomal abnormalities. NSC 617145 shows selective for WRN over BLM, FANCJ, ChlR1, RecQ, and UvrD helicases .
    NSC 617145
  • HY-148740
    Werner syndrome RecQ helicase-IN-3

    		DNA/RNA Synthesis Cancer
    Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity .
    Werner syndrome RecQ helicase-IN-3
  • HY-175750
    MOMA-341

    		DNA/RNA Synthesis Cancer
    MOMA-341 is a selective Werner RecQ like helicase (WRN) inhibitor. MOMA-341 binds to WRN at cysteine 727 through an allosteric and ATP-competitive binding mechanism. MOMA-341 has antitumor activity and can be used for advanced and metastatic solid tumors research .
    MOMA-341
  • HY-128712
    NCGC00029283

    		DNA/RNA Synthesis Cancer
    NCGC00029283 is a werner syndrome helicase-nuclease (WRN) helicase inhibitor with IC50s of 2.3 μM, 12.5 μM, and 3.4 μM for WRN, BLM and FANCJ helicase, respectively .
    NCGC00029283
  • HY-148741
    Werner syndrome RecQ helicase-IN-4

    		DNA/RNA Synthesis Cancer
    Werner syndrome RecQ helicase-IN-4 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-4 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-4 shows anticancer activity .
    Werner syndrome RecQ helicase-IN-4
  • HY-114221
    Org 48762-0

    UR13870

    		 p38 MAPK Inflammation/Immunology
    Org 48762-0 (UR13870) is a potent, orally active and selective p38 inhibitor with an EC50 of 0.1 μM for p38α kinase. Org 48762-0 shows a high degree of kinase selectivity for p38α and p38β over other kinases. Org 48762-0 reduces Lipopolysaccharides (HY-D1056) (LPS)-induced TNFα release. Org 48762-0 can be used for the study of rheumatoid arthritis (RA) and Werner syndrome .
    Org 48762-0
  • HY-148700
    Werner syndrome RecQ helicase-IN-2

    		DNA/RNA Synthesis Cancer
    Werner syndrome RecQ helicase-IN-2 (example 57) is a potent Werner syndrome RecQ DNA helicase enzyme (WRN) inhibitor and can be used in cancer research .
    Werner syndrome RecQ helicase-IN-2
  • HY-156580
    WRN inhibitor 4

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 4 is a Werner Syndrome ATP-dependent helicase (WRN) inhibitor. WRN inhibitor 4 can be used for cancer research .
    WRN inhibitor 4
  • HY-149887
    H3B-968
    1 Publications Verification

    		 DNA/RNA Synthesis Cancer
    H3B-968 is the ATP-competitive inhibitor of Werner syndrome protein (WRN) with an IC50 of about 10 nM .
    H3B-968
  • HY-153973
    WRN inhibitor 2

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 2 (example 118) is a WRN (Werner Syndrome ATP dependent helicase enzyme) inhibitor, with pIC50 ≥ 7.0 .
    WRN inhibitor 2
  • HY-169423
    WRN inhibitor 17

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 17 (Compound 250) is an orally active Werner Syndrome ATP dependent helicase enzyme (WRN) inhibitor, in particular inhibit WRN helicase domain activity. WRN inhibitor 17 is promising for research of cancers .
    WRN inhibitor 17
  • HY-178991
    WRN-IN-21

    		DNA/RNA Synthesis Cancer
    WRN-IN-21 (Compound 11b) is a WRN helicase inhibitor with pIC50 values for WRN and BLM helicases of 3.6 and 5.4 respectively. WRN-IN-21 can be used for the study of MSI-related cancers .
    WRN-IN-21
  • HY-176912
    WRN-IN-22

    		DNA/RNA Synthesis Cancer
    WRN-IN-22 (compound A01) is a potent Werner syndrome RecQ helicase (WRN) inhibitor (IC50 < 100 nM). WRN-IN-22 can be used for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer research, such as colorectal, gastric, prostate and endometrial cancer .
    WRN-IN-22
  • HY-163797
    WRN inhibitor 10

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 10 (Compound P24) is an inhibitor for the Werner helicase WRN with an IC50 of 1.1 nM. WRN inhibitor 10 inhibits the proliferation of cancer cell SW48 with IC50 of 39 nM. WRN inhibitor 10 exhibits good liver microsomal stability and film permeability. WRN inhibitor 10 exhibits good pharmacokinetic characteristics in CD-1 mice .
    WRN inhibitor 10
  • HY-179326
    WRN-IN-23

    		DNA/RNA Synthesis Cancer
    WRN-IN-23 is a Werner Syndrome helicase enzyme (WRN) inhibitor. WRN-IN-23 inhibits the ATP-dependent helicase domain activity of WRN. WRN-IN-23 can be used for the research of cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR) .
    WRN-IN-23
  • HY-182313
    WRN-IN-25

    		DNA/RNA Synthesis Cancer
    WRN-IN-25 is an allosteric Werner syndrome helicase (WRN) inhibitor with an IC50 of 15 nM and a Kd of 54 nM. WRN-IN-25 induces DNA damage, reduces cell viability, and exhibits synthetic lethality in WRN-driven high microsatellite instability cancer cells. WRN-IN-25 can be used in research related to microsatellite instability cancers .
    WRN-IN-25
  • HY-182634
    NCGC00063279

    		DNA/RNA Synthesis Phosphatase Cancer
    NCGC00063279 is a reversible Werner Syndrome Helicase-Nuclease (WRN) helicase inhibitor with modest selectivity over BLM and FANCJ helicases, and does not inhibit WRN exonuclease activity at active concentrations. NCGC00063279 inhibits Hematopoietic Protein Tyrosine Phosphatase (HePTP) and reduces proliferation of cancer cells. NCGC00063279 can be used for the research of osteosarcoma .
    NCGC00063279
  • HY-181562
    WRN-IN-24

    		DNA/RNA Synthesis Cancer
    WRN-IN-24 is an orally active allosteric covalent Werner syndrome helicase (WRN) inhibitor with an IC50 of 201 nM. WRN-IN-24 binds to a novel allosteric cavity, forms an additional hydrogen bond with K894, and functionally inhibits WRN activity. WRN-IN-24 inhibits colorectal cancer cells proliferation and exerts dose-dependent antitumor activity in xenograft mouse models. WRN-IN-24 can be used for the research of microsatellite instability-high cancers, including colorectal cancer .
    WRN-IN-24
  • HY-183610
    WRN-IN-26

    		DNA/RNA Synthesis PAK Cancer
    WRN-IN-26 is an orally active Werner syndrome helicase (WRN) inhibitor with a human Ki value of 58.7 μM and an IC50 value of 0.026 μM. WRN-IN-26 selectively targets the cysteine residues of WRN. WRN-IN-26 induces the expression of p21 protein in MSI-H tumor cells. WRN-IN-26 inhibits the growth of MSI-H tumor cells and exhibits potent in vivo efficacy in MSI-H xenograft tumor models. WRN-IN-26 can be used for the research of microsatellite instability-high (MSI-H) cancers .
    WRN-IN-26

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: